B. Metzler seel. Sohn & Co. Holding AG Invests $2.22 Million in Insulet Co. (NASDAQ:PODD)

B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in Insulet Co. (NASDAQ:PODD) in the third quarter, HoldingsChannel reports. The fund purchased 9,542 shares of the medical instruments supplier’s stock, valued at approximately $2,221,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Blue Trust Inc. raised its stake in shares of Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 58 shares during the period. International Assets Investment Management LLC bought a new position in shares of Insulet during the second quarter valued at approximately $32,000. Venturi Wealth Management LLC raised its holdings in shares of Insulet by 633.3% in the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 133 shares during the period. UMB Bank n.a. lifted its stake in shares of Insulet by 81.0% during the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after acquiring an additional 81 shares during the last quarter. Finally, CVA Family Office LLC grew its position in Insulet by 138.1% in the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 145 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on PODD shares. UBS Group lifted their target price on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research report on Friday, August 9th. Citigroup lifted their price objective on shares of Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a report on Tuesday, October 1st. BTIG Research upped their target price on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Raymond James lifted their price target on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. Finally, Piper Sandler increased their price objective on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, Insulet currently has an average rating of “Moderate Buy” and an average price target of $253.27.

Insulet Trading Down 1.3 %

Shares of NASDAQ PODD opened at $262.99 on Friday. The business has a fifty day moving average price of $240.74 and a 200 day moving average price of $209.99. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $279.40. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock has a market capitalization of $18.45 billion, a P/E ratio of 45.03, a price-to-earnings-growth ratio of 4.01 and a beta of 1.22.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.